EUVIMEDEUVIMED entdecken
Metaanalyse

Pharmacokinetic and pharmacodynamic modelling of vedolizumab in Crohn’s disease using summary level data and its application to model-informed precision dosing

Koji Kimura iD, Atsushi Yoshida

Journal of Pharmacy and Pharmacology · 2025

DOI: 10.1093/jpp/rgaf123 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Journal of Pharmacy and Pharmacology, 2025. Verfasst von Koji Kimura und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Evaluation of Drug Efficacy, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo 192-0392, Japan. Hauptthemen laut MEDLINE: Crohn Disease, Antibodies, Monoclonal, Humanized, Gastrointestinal Agents, Models, Biological. Die Arbeit nennt 49 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To optimize vedolizumab therapy for Crohn’s disease, this study aimed to construct a pharmacokinetic/pharmacodynamic (PK/PD) model by applying model-based meta-analysis (MBMA) methods to summary-level clinical data (SLD) and to evaluate a model-informed precision dosing (MIPD) approach based on the model.

Methods

We used the results of previously reported PK analysis. For PD analysis, summary-level Crohn’s Disease Activity Index (CDAI) data were extracted from Phase III trials. Following covariate analysis, the final model was fitted using the Markov chain Monte Carlo Bayesian method (four chains; burn-in 10 000; 100 000 sampling) in NONMEM. The final model was leveraged for empirical Bayes estimation in an MIPD case study. Key findings The posterior estimates of the final model indicated adequate between-chain mixing and acceptable precision ($\hat{R}$<1.01; most achieved bulk and tail effective sample size > 1000 with lowest values of 541 and 820, respectively). In the case study, the MIPD approach based on the final model accurately predicted the time course of the CDAI with minimal.

Conclusion

PK/PD modelling by applying MBMA methods to SLD is feasible when access to individual patient data (IPD) is restricted. The MIPD approach demonstrated promising predictive accuracy. Future confirmatory studies using IPD are warranted to establish impact on patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseAntibodies, Monoclonal, HumanizedGastrointestinal AgentsModels, BiologicalHumansBayes TheoremMonte Carlo MethodClinical Trials, Phase III as TopicDose-Response Relationship, DrugMarkov Chains

Stichwörter der Autor:innen

Crohn’s diseasemodel-based meta-analysismodel-informed precision dosingvedolizumab

Substanzen

vedolizumabAntibodies, Monoclonal, HumanizedGastrointestinal Agents

Autor:innen und Institutionen

  • Department of Clinical Evaluation of Drug Efficacy, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo 192-0392, Japan.
  • Center for Gastroenterology and Inflammatory Bowel Disease, Ofuna Chuo Hospital, Kamakura, Kanagawa 247-0056, Japan.

ORCID-Profile: Koji Kimura

Zitieren

APA

Kimura, K., & Yoshida, A. (2025). Pharmacokinetic and pharmacodynamic modelling of vedolizumab in Crohn’s disease using summary level data and its application to model-informed precision dosing. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgaf123

Vancouver

Kimura K, Yoshida A. Pharmacokinetic and pharmacodynamic modelling of vedolizumab in Crohn’s disease using summary level data and its application to model-informed precision dosing. Journal of Pharmacy and Pharmacology. 2025. doi:10.1093/jpp/rgaf123

BibTeX
@article{Kimura2025,
  author = {Kimura, Koji and Yoshida, Atsushi},
  title = {Pharmacokinetic and pharmacodynamic modelling of vedolizumab in Crohn’s disease using summary level data and its application to model-informed precision dosing},
  journal = {Journal of Pharmacy and Pharmacology},
  year = {2025},
  doi = {10.1093/jpp/rgaf123}
}
Kostenlos starten →